Update shared on 11 Dec 2025
Analysts have nudged their price target on Vitrolife slightly higher to SEK 193.50 from SEK 193.00, citing marginally stronger long term revenue growth expectations that more than offset a modest uptick in the assumed discount rate and a slightly lower forecast profit margin.
Valuation Changes
- Fair Value Estimate: unchanged at SEK 193.5 per share, indicating no revision to the intrinsic value despite minor model adjustments.
- Discount Rate: risen slightly from 5.29 percent to 5.31 percent, reflecting a marginally higher assumed risk profile or cost of capital.
- Revenue Growth: risen slightly from 6.81 percent to 7.15 percent, implying a modestly more optimistic outlook for long term top line expansion.
- Net Profit Margin: fallen slightly from 19.68 percent to 19.33 percent, incorporating expectations of somewhat higher costs or pricing pressure.
- Future P/E: risen slightly from 36.25x to 36.58x, suggesting a marginally higher valuation multiple applied to forward earnings.
Have other thoughts on Vitrolife?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.